

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Versant Vantage I, L.P.</u> <hr/> (Last) (First) (Middle) ONE SANSOME STREET, SUITE 3630 <hr/> (Street) SAN FRANCISCO CA 94104 <hr/> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Aprrea Therapeutics, Inc. [ APRE ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 05/18/2020	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	05/18/2020		J <sup>(1)</sup>		116,664	D	\$0	216,669	D <sup>(2)</sup>	
Common Stock	05/18/2020		J <sup>(3)</sup>		1,750	A	\$0	1,750	I	See footnotes <sup>(4)</sup>
Common Stock	05/18/2020		J <sup>(5)</sup>		1,750	D	\$0	0	I	See footnotes <sup>(4)</sup>
Common Stock	05/18/2020		J <sup>(6)</sup>		1,734	A	\$0	1,734	I	See footnotes <sup>(7)</sup>
Common Stock	05/18/2020		J <sup>(8)</sup>		1,734	D	\$0	0	I	See footnotes <sup>(7)</sup>

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					

1. Name and Address of Reporting Person\*  
Versant Vantage I, L.P.  


---

 (Last) (First) (Middle)  
 ONE SANSOME STREET, SUITE 3630  


---

 (Street)  
 SAN FRANCISCO CA 94104  


---

 (City) (State) (Zip)

1. Name and Address of Reporting Person\*  
Versant Vantage I GP, L.P.  


---

 (Last) (First) (Middle)  
 ONE SANSOME STREET, SUITE 3630  


---

 (Street)  
 SAN FRANCISCO CA 94104  


---

 (City) (State) (Zip)

FRANCISCO

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

Versant Vantage I GP-GP, LLC

(Last) (First) (Middle)

ONE SANSOME STREET, SUITE 3630

(Street)

SAN FRANCISCO CA 94104

(City) (State) (Zip)

**Explanation of Responses:**

1. Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Vantage I, L.P. ("Vantage") without consideration to its partners.
2. These Shares are directly held by Vantage. Versant Vantage I GP-GP, LLC ("Vantage GP-GP") is the general partner of Versant Vantage I GP, L.P. ("Vantage GP"), which is the general partner of Vantage. Each of Vantage GP-GP and Vantage GP may be deemed to indirectly beneficially own the shares beneficially owned by Vantage, but each disclaims such beneficial ownership except to the extent of its pecuniary interest therein.
3. Represents a change in the form of ownership of Vantage GP by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by Vantage.
4. The shares are held by Vantage GP.
5. Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Vantage GP without consideration to its partners.
6. Represents a change in the form of ownership of Vantage GP-GP by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by Vantage GP.
7. The shares are held by Vantage GP-GP.
8. Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Vantage GP-GP without consideration to its members.

Versant Vantage I, L.P. By:  
Versant Vantage I GP, L.P. Its:  
General Partner By: Versant 05/20/2020  
Vantage I GP-GP, LLC. Its:  
General Partner By: /s/ Robin  
L. Praeger, Managing Director  
Versant Vantage I GP, L.P. By:  
Versant Vantage I GP-GP,  
LLC Its: General Partner By: 05/20/2020  
/s/ Robin L. Praeger,  
Managing Director  
Versant Vantage I GP-GP,  
LLC By: /s/ Robin L. Praeger, 05/20/2020  
Managing Director

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.